Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 11/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.56 |
| ▸ | NPY1R | P25929 | 8/20 | 0.56 |
| ▸ | FURIN | P09958 | 1/20 | 0.51 |
| ▸ | NPY2R | P49146 | 6/20 | 0.51 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31462936 | 0.93 | NPY4R (0.54) | NPY4RNPY5RNPY1RFURINNPY2R | |
| SCHEMBL31720889 | 0.91 | NPY4R (0.54) | NPY4RNPY5RNPY1RNPY2RQRFPR | |
| SCHEMBL30463288 | 0.90 | SLC15A2 (0.48) | NPY4RNPY5RNPY1RNPY2RQRFPR | |
| SCHEMBL7861254 | 0.90 | NPY4R (0.47) | NPY4RNPY5RNPY1RFURINNPY2R | |
| SCHEMBL30692729 | 0.90 | GNPAT (0.54) | NPY4RNPY5RNPY1RNPY2RQRFPR | |
| SCHEMBL29447211 | 0.90 | GNPAT (0.54) | NPY4RNPY5RNPY1RNPY2RQRFPR | |
| SCHEMBL7861255 | 0.90 | NPY4R (0.47) | NPY4RNPY5RNPY1RFURINNPY2R | |
| SCHEMBL30974473 | 0.90 | NPY5R (0.54) | NPY4RNPY5RNPY1RNPY2RQRFPR | |
| SCHEMBL30632623 | 0.90 | NPY4R (0.60) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL7867783 | 0.89 | NPY4R (0.53) | NPY4RNPY5RNPY1RFURINNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11560422-B2 | Sulfonamide-containing linkage systems for drug conjugates | ZYMEWORKS INC. | 2023-01-24 | — | — | US | claimed |
| US-20230265173-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | ZYMEWORKS BC INC. (CA) | 2023-08-24 | — | — | US | disclosed |
| US-11560422-B2 | Sulfonamide-containing linkage systems for drug conjugates | ZYMEWORKS INC. | 2023-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265173-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | MPST, TPST2, SULT1A1 | NPY4R 2691/4885NPY5R 2137/4885NPY1R 1554/4885 |
| US-11560422-B2 | Sulfonamide-containing linkage systems for drug conjugates | MPST, TPST2, SULT1A1 | NPY4R 2691/4885NPY5R 2137/4885NPY1R 1554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.